RedPath Receives Two Technology Grants for Development of PathFinderTG® Platform
PITTSBURGH, PA., Nov. 8 -- RedPath Integrated Pathology, Inc. ("RedPath"), a cancer molecular diagnostics company headquartered in Pittsburgh, PA, announced that it has received two technology grants from The Internal Revenue Service to support continued development of the company’s flagship PathFinderTG molecular diagnostics platform. The two grants totaling $488,958 were awarded through the IRS Qualifying Therapeutic Discovery Project Program.
The first grant of $244,479 will support continuing development and refinement of the company’s PathFinderTG Pancreatic Cyst Analysis technology for improved characterization and diagnosis of potentially cancerous pancreatic cysts. The second grant of $244,479 will support continuing development of the PathFinderTG technology for distinguishing metastatic vs. new primary cancer (PathFinderTG MvP Dx™). This test is used to determine the relationship of multiple tumors, for example tumors that are identified at the same time or a new tumor discovered years later.
RedPath’s PathFinderTG Pancreatic Cyst Analysis for pancreatic cancer recently received a positive Medicare Local Coverage Determination which stated that the test will be covered as a “reasonable and necessary” service for the analysis of pancreatic cysts and masses when traditional diagnostic evaluations are inconclusive. PathFinderTG is the keystone of RedPath’s comprehensive menu of tests for the characterization of pancreatic cysts. The company’s unique approach integrates mutational analysis of DNA in the cyst with other tests and clinical data to provide gastroenterologists and surgeons an unparalleled level of detailed diagnostic information.
PathFinderTG MvP Dx compares mutational DNA fingerprints obtained by microdissection of two or more tumors to determine the relationship between them. This approach is most useful when microscopic and traditional laboratory analysis cannot determine whether the tumors represent metastasis from a single cancer or whether the patient actually has two different cancers. This important distinction gives the physician the ability to make personalized therapeutic decisions most appropriate for their patients. The company presented data on this application at last week’s American Society of Clinical Pathology meeting in San Francisco, CA.
About PathFinderTG® Analysis
PathFinderTG is a molecular analysis of mutations in genomic DNA for cases where traditional pathology or other diagnostics tests such as imaging, cytology and fluid chemistry analysis result in an "indeterminate", "suspicious", or "atypical" diagnoses. The objective molecular information from PathFinderTG can help resolve diagnostic dilemmas and lead to a more personalized treatment plan.
About RedPath Integrated Pathology, Inc.
RedPath is a genomics-based molecular diagnostics company that provides complex cancer diagnostic tests for pathologists, oncologists, surgeons, and other clinicians. RedPath’s pathologists integrate its patented molecular-based analysis, PathFinderTG, with the results of routine biopsy, cytology, and fluid chemistry studies to render earlier, more informative diagnoses to improve patient outcomes and reduce healthcare costs. For more information, please visit http://www.redpathip.com.